Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Daily administration of Limosilactobacillus mucosae DPC 6426 had negligible effects on blood lipids in mildly hypercholesterolaemic adults

O'Donovan, Aoife N. ; Fouhy, Fiona ; Grimaud, Ghjuvan LU orcid ; London, Lis E. E. ; Doolan, Andrea ; Anesi, Andrea ; Mattivi, Fulvio ; Ross, R. Paul ; Caplice, Noel and Stanton, Catherine (2026) In Scientific Reports
Abstract
Among the recommendations to prevent heart disease is the maintenance of
normal blood cholesterol levels, through the consumption of a
cardioprotective diet, and if necessary, the use of therapeutics such as
statins. Alterations in the gut microbiota have previously been
associated with the development of obesity, insulin resistance and
increased risk of developing cardiovascular disease (CVD). Probiotics
have since emerged as a potential therapeutic strategy, aimed at
reversing the alterations to the gut microbiome. Indeed, we had
previously found that ingestion of Limosilactobacillus mucosae
DPC 6426 had significantly lowered both blood cholesterol and
triglyceride levels in a... (More)
Among the recommendations to prevent heart disease is the maintenance of
normal blood cholesterol levels, through the consumption of a
cardioprotective diet, and if necessary, the use of therapeutics such as
statins. Alterations in the gut microbiota have previously been
associated with the development of obesity, insulin resistance and
increased risk of developing cardiovascular disease (CVD). Probiotics
have since emerged as a potential therapeutic strategy, aimed at
reversing the alterations to the gut microbiome. Indeed, we had
previously found that ingestion of Limosilactobacillus mucosae
DPC 6426 had significantly lowered both blood cholesterol and
triglyceride levels in a pre-clinical apoE mouse model, as well as
modulating the gut microbiota, suggesting strain-specific
cardiometabolic potential. To investigate the translational relevance of
these findings in humans, we conducted a randomised, double-blind,
placebo-controlled clinical trial which assessed the effects of daily
administration of the strain at a dose of 3.8 × 109 CFU/per
day, in mildly hypercholesterolaemic adults, on blood lipid profiles and
the gut microbiota composition. Results demonstrated, despite
successful gastrointestinal transit and recovery of Lactobacillus spp., that Limosilactobacillus mucosae
DPC 6426 was not superior to placebo in modifying blood lipid
concentrations or the gut microbiota composition in healthy, mildly
hypercholesterolaemic adults. Such findings highlight the complexity of
translating probiotic-associated metabolic benefits from preclinical
apoE mouse models to healthy human participants. Further investigations
are warranted to ascertain whether the probiotic dose administered in
this study was insufficient to translate from the pre-clinical apoE
mouse model in such a human cohort. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
epub
subject
in
Scientific Reports
publisher
Nature Publishing Group
ISSN
2045-2322
DOI
10.1038/s41598-026-66210-z
language
English
LU publication?
yes
id
88fbbc14-121c-46c5-9d19-9daa8538ff04
date added to LUP
2026-09-28 15:46:30
date last changed
2026-10-09 13:53:05
@article{88fbbc14-121c-46c5-9d19-9daa8538ff04,
  abstract     = {{Among the recommendations to prevent heart disease is the maintenance of<br>
 normal blood cholesterol levels, through the consumption of a <br>
cardioprotective diet, and if necessary, the use of therapeutics such as<br>
 statins. Alterations in the gut microbiota have previously been <br>
associated with the development of obesity, insulin resistance and <br>
increased risk of developing cardiovascular disease (CVD). Probiotics <br>
have since emerged as a potential therapeutic strategy, aimed at <br>
reversing the alterations to the gut microbiome. Indeed, we had <br>
previously found that ingestion of <i>Limosilactobacillus mucosae</i> <br>
DPC 6426 had significantly lowered both blood cholesterol and <br>
triglyceride levels in a pre-clinical apoE mouse model, as well as <br>
modulating the gut microbiota, suggesting strain-specific <br>
cardiometabolic potential. To investigate the translational relevance of<br>
 these findings in humans, we conducted a randomised, double-blind, <br>
placebo-controlled clinical trial which assessed the effects of daily <br>
administration of the strain at a dose of 3.8 × 10<sup>9</sup> CFU/per <br>
day, in mildly hypercholesterolaemic adults, on blood lipid profiles and<br>
 the gut microbiota composition. Results demonstrated, despite <br>
successful gastrointestinal transit and recovery of <i>Lactobacillus</i> spp., that <i>Limosilactobacillus mucosae</i><br>
 DPC 6426 was not superior to placebo in modifying blood lipid <br>
concentrations or the gut microbiota composition in healthy, mildly <br>
hypercholesterolaemic adults. Such findings highlight the complexity of <br>
translating probiotic-associated metabolic benefits from preclinical <br>
apoE mouse models to healthy human participants. Further investigations <br>
are warranted to ascertain whether the probiotic dose administered in <br>
this study was insufficient to translate from the pre-clinical apoE <br>
mouse model in such a human cohort.}},
  author       = {{O'Donovan, Aoife N. and Fouhy, Fiona and Grimaud, Ghjuvan and London, Lis E. E. and Doolan, Andrea and Anesi, Andrea and Mattivi, Fulvio and Ross, R. Paul and Caplice, Noel and Stanton, Catherine}},
  issn         = {{2045-2322}},
  language     = {{eng}},
  publisher    = {{Nature Publishing Group}},
  series       = {{Scientific Reports}},
  title        = {{Daily administration of <i>Limosilactobacillus mucosae</i> DPC 6426 had negligible effects on blood lipids in mildly hypercholesterolaemic adults}},
  url          = {{http://dx.doi.org/10.1038/s41598-026-66210-z}},
  doi          = {{10.1038/s41598-026-66210-z}},
  year         = {{2026}},
}